Adap­ti­m­mune gets a par­tial hold on piv­otal T-cell study, but it seems OK to breathe now

The FDA is tap­ping the brakes on one of Adap­ti­m­mune T-cell stud­ies, look­ing for some clar­i­fi­ca­tions be­fore it gives the green light to start test­ing NY-ESO SPEAR T-cell ther­a­py in myx­oid round cell li­posar­co­ma.

No doubt there were a few skipped heart beats among in­vestors, but the UK biotech $ADAP hur­ried on to ex­plain that reg­u­la­tors are sim­ply look­ing to get a few an­swers for a reg­is­tra­tion tri­al that has yet to start re­cruit­ing pa­tients.

Im­muno-on­col­o­gy has ex­plod­ed in re­cent years, in a good way. New play­ers like Adap­ti­m­mune have at­tract­ed bil­lions in in­vest­ment cash. But as Juno demon­strat­ed re­cent­ly with its lead CAR-T study, a sud­den halt fol­low­ing the death of pa­tients can raise ques­tions about the en­tire field.

It’s im­por­tant to note, though, that the FDA lift­ed its hold on Juno just days af­ter im­pos­ing a clin­i­cal hold on the study, sat­is­fied that the biotech had an­swered its ques­tions about safe­guard­ing pa­tients from any fur­ther un­nec­es­sary risk. And Bank of Amer­i­ca an­a­lysts note that this pause is not tied to the use of flu­dara­bine, which Juno says was re­spon­si­ble for killing sev­er­al pa­tients.

“We spoke with man­age­ment who re­it­er­at­ed that the in­for­ma­tion re­quest­ed by FDA is clar­i­fi­ca­tion of de­f­i­n­i­tions rather than re­lat­ed to flu­dara­bine use or CMC man­u­fac­tur­ing is­sues that have plagued oth­er T cell ther­a­pies. ADAP plans to re­spond to the FDA short­ly and ex­pects the FDA to take 30 days to re­view their re­spons­es, re­sult­ing in a de­lay in the tri­al time­line.”

What­ev­er the case, Adap­ti­m­mune shares slipped 4% in af­ter mar­ket trad­ing as some ner­vous in­vestors fret­ted.

James No­ble, Adap­ti­m­mune CEO

“Adap­ti­m­mune is run­ning a num­ber of dif­fer­ent stud­ies with its NY-ESO pro­gram and con­tin­ues to en­roll pa­tients in syn­ovial sar­co­ma, ovar­i­an, and lung can­cer tri­als in the U.S.,” said James No­ble, Adap­ti­m­mune CEO, in a state­ment. “We have been in di­a­logue with the FDA since achiev­ing break­through sta­tus ear­li­er this year and this par­tial clin­i­cal hold re­quires a num­ber of ques­tions to be an­swered be­fore we can start a new MR­CLS tri­al in­tend­ed to be used for reg­is­tra­tion pur­pos­es. We will be pro­vid­ing a full re­sponse to the FDA short­ly and will up­date the mar­kets when we have fur­ther news to re­port.”

Adap­ti­m­mune’s lead pro­gram is a SPEAR T-cell ther­a­py tar­get­ing the NY-ESO can­cer anti­gen. The com­pa­ny is a spe­cial­ist in TCR tech.

From left to right: Lilian Kim, Associate Director Business Development; John Moller, CEO; Yooni Kim, Executive Director, Asia Operations; Michelle Park, Director South Korea Operations.

Novotech CRO sees 26% growth in Asia tri­al ac­tiv­i­ty from biotechs, but still plen­ty of ca­pac­i­ty

As the Asia-Pacific clinical trials sector continues to grow rapidly, Novotech the Asia-Pacific-based CRO is seeing biotech clinical activity up by 26%. But says there is still plenty of capacity in the region that features advanced medical facilities, supportive regulatory environments, and more than 2.3 billion people, largely treatment naïve, living in urban areas.

China, South Korea and Australia have the most studies registered as recruiting or about to recruit according to ClinicalTrials.Gov.

Eye­ing $86M, Galera leads a pack of three mod­est biotech IPOs push­ing out of high pro­file stum­bles

Exactly one year after kicking off a pivotal Phase III study for its lead drug — a companion for cancer patients receiving radiotherapy — Galera is looking to the Nasdaq for some new cash to complete the clinical work and fuel its commercial drive.

CEO Mel Sorensen has penciled in an $86 million ask, which was filed on the same day as liver disease company 89bio and rare disease diagnostics shop Centogene. The trio marks the first batch of IPO filings in the wake of two highly anticipated but ultimately disappointing public debuts by BioNTech and Vir, signaling dwindling biotech fervor on Wall Street. 89bio and Centogene are seeking $70 million and $69 million, respectively.

Pelosi drug pric­ing bill promis­es sav­ings, but could gag R&D — analy­sis

The Democrats’ drug pricing bill — unveiled by Speaker Nancy Pelosi last month — could save Medicare spending by $345 billion over a six year period, a new analysis suggests. But the venomous climate of impeachment proceedings and the intensifying discord between the Democrat-controlled House and Republican-majority Senate portends the bill will unlikely ever become law.

Technically, both sides of the aisle agree drug prices in the United States need some lowering. The Democrats’ bill, H.R.3 – Lower Drug Costs Now Act of 2019, is engineered to empower the HHS to negotiate prices for the 125 most expensive prescription drugs without at least two competitors — the Trump administration has already backed such a measure for the Veterans Association. Under the bill, prices for this category of medicines are not intended to exceed 120% of the average price in certain other countries (Australia, Canada, France, Germany and the United Kingdom), akin to a proposal floated by Trump earlier this year, which suggested prices be pegged against what other nations were paying as part of an “international pricing index”.

Hal Barron and Rick Klausner (GSK, Lyell)

Ex­clu­sive: GSK’s Hal Bar­ron al­lies with Rick Klaus­ner’s $600M cell ther­a­py start­up, look­ing to break new ground blitz­ing sol­id tu­mors

LONDON — Chances are, you’ve heard little or nothing about Rick Klausner’s startup Lyell. But that ends now.

Klausner, the former head of the National Cancer Institute, former executive director for global health at the Gates Foundation, co-founder at Juno and one of the leaders in the booming cell therapy field, has brought together one of the most prominent teams of scientists tackling cell therapy 2.0 — highlighted by a quest to bridge a daunting tech gap that separates some profound advances in blood cancers with solid tumors. And today he’s officially adding Hal Barron and GlaxoSmithKline as a major league collaborator which is pitching in a large portion of the $600 million he’s raised in the past year to make that vision a reality.

“We’ve being staying stealth,” Klausner tells me, then adding with a chuckle: “and going back to stealth after this.”

“Cell therapy has a lot of challenges,” notes Barron, the R&D chief at GSK, ticking off the resistance put up by solid tumors to cell therapies, the vein-to-vein time involved in taking immune cells out of patients, engineering them to attack cancer cells, and getting them back in, and more. “Over the years Rick and I talked about how it would be wonderful to take that on as a mission.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily — and it's free.

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

In a rare twist for Eli Lilly’s historically slow-moving R&D group, the pharma giant has seized bragging rights to a first-in-class new drug approval. And all signs point to an aggressive marketing followup as they look to outclass some major franchise rivals hobbled by internal dissension.

The FDA came through with an OK for lasmiditan on Friday evening, branding it as Reyvow and lining it up — once a substance classification comes through from the DEA — for a major market release. The oral drug binds to 5-HT1F receptors and is designed to stop an acute migraine after it starts. That makes it a complementary therapy to their CGRP drug Emgality, which has a statistically significant impact on preventing attacks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily — and it's free.

Pfizer, South San Francisco — Jeff Rumans for Endpoints News

UP­DAT­ED: Pfiz­er takes aim at a flag­ship fran­chise at Sanofi and Re­gen­eron — and scores a few di­rect hits

Count Pfizer in as a top player in the blockbuster game of JAK1 inhibitors.

Over the weekend the pharma giant posted some stellar Phase III efficacy data for their heavyweight contender abrocitinib in atopic dermatitis (eczema) that lines up ahead of a booming Dupixent (dupilumab), a blockbuster in the portfolios of Regeneron and Sanofi. And they put some real distance ahead of Eli Lilly’s trailing Olumiant, which made a delayed initial arrival on the market for rheumatoid arthritis after the FDA hobbled it with some additional hurdles on safety concerns.

JADE-MONO-1 scores well for Pfizer, teeing up what will be an intensely followed breakdown of the JADE MONO-2 data, which the pharma giant recently top-lined as “similar” to the first Phase III when tested against a placebo — a control group that has been easily outclassed by all the drugs in this market niche.

As of now, Pfizer looks to be equipped to run into the review stage — advantaged by a breakthrough therapy designation that is intended to speed up the regulatory process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily — and it's free.

Patrick Mahaffy, Getty Images

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Clovis investors have cleared a major hurdle in their long-running case against the board of directors, with a Delaware court making a rare finding that they had a strong enough case against the board to proceed with the action.

In a detailed ruling at the beginning of the month that’s been getting careful scrutiny at firms specializing in biotech and corporate governance, the Delaware Court of Chancery found that the attorneys for the investors had made a careful case that the board — a collection of experts that includes high-profile biotech entrepreneurs, a Harvard professor and well-known investigator as well as Clovis CEO Patrick Mahaffy — repeatedly ignored obvious warnings that Mahaffy’s executive crew was touting inflated, unconfirmed data for their big drug Roci. Serious safety issues were also reportedly overlooked while the company continued a fundraising campaign that brought in more than a half-billion dollars. And that leaves the board open to claims related to their role in the fiasco.

The bottom line:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bill Gates backs Gink­go Biowork­s' $350M raise to fu­el the buzzy syn­thet­ic bi­ol­o­gy 'rev­o­lu­tion'

If you want to understand Ginkgo Bioworks, the name should suffice: Bioworks, a spin off “ironworks,” that old industrial linchpin devoted to leveraging scale as a wellspring for vast new industries capable of remaking society. Ginkgo wants to be the ironworks for the revolution it’s heralded with as much fanfare as they can, playing off of one of the buzziest technologies in biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily — and it's free.

UCB bags a ri­val to Soliris in $2.1B buy­out deal — but will an in­creas­ing­ly vig­i­lant FTC sign off?

UCB is buying out Ra Pharma $RARX, announcing an acquisition deal that rings up at $48 a share, or $2.1 billion net of cash, and puts them toe-to-toe with Alexion on a clinical showdown.

Ra shares closed at $22.70 on Wednesday.

There’s a small pipeline in play at Ra, but UCB is going for the lead drug — a C5 inhibitor called zilucoplan in Phase III for myasthenia gravis (MG) looking to play rival to Alexion’s Soliris. Soliris has the market advantage, though, with a much earlier approval in MG in late 2017 that UCB feels confident in challenging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily — and it's free.